Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antibiotics >  Aminoglycosides drugs >  KANAMYCIN SULFATE

KANAMYCIN SULFATE

Basic information Safety Supplier Related

KANAMYCIN SULFATE Basic information

Product Name:
KANAMYCIN SULFATE
Synonyms:
  • 2-(Aminomethyl)-6-[4,6-diamino-3-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol sulfate
  • C18H36-37N4-5O10-11H2SO4
  • Kanmycin MonosulfateSulfate
  • kanamycin sulfate mixture of components A
  • KANAMYCIN SULFATE MIXTURE OF COMPONENTS A,B AND C
  • KANAMYCIN MONOSULFATE
  • KANAMYCIN MONOSULFATE SALT
  • KANAMYCIN MONO SULPHATE
CAS:
70560-51-9
MF:
C18H38N4O15S
MW:
582.58
EINECS:
684-844-0
Mol File:
70560-51-9.mol
More
Less

KANAMYCIN SULFATE Chemical Properties

storage temp. 
2-8°C
solubility 
H2O: 10-50 mg/mL As a stock solution. Stock solutions should be stored at 2-8°C. Stable at 37°C for 5 days.
form 
powder
color 
white to off-white
BRN 
3874279
CAS DataBase Reference
70560-51-9(CAS DataBase Reference)
More
Less

Safety Information

Hazard Codes 
Xi,T
Risk Statements 
61
Safety Statements 
22-24/25-53-45-36/37/39
WGK Germany 
3
RTECS 
NZ3225030

MSDS

More
Less

KANAMYCIN SULFATE Usage And Synthesis

Originator

Kantrex,Bristol,US,1958

Uses

Kanamycin Sulfate is an aminoglycoside-antibiotic with broad antibacterial spectrum.

Manufacturing Process

As described in US Patent 2,931,798, Streptomyces kanamyceticus (K2-J) was first cultured in shake flasks in the following media: (a) 0.75% meat extract, 0.75% peptone, 0.3% NaCl, with 1.0% of starch, dextrin, maltose, glucose, lactose, sucrose or glycerol; or (b) 2.0% soybean meal, 0.05% KCl, 0.05% MgSO4 · 7H2O, 0.5% NaCl, 0.2% NaNO3, with 1.0% of starch, dextrin, maltose, glucose, lactose, sucrose or glycerol. The initial pH of all media was adjusted to 7.0. After 24 to 48 hours shaking in some cases the pH decreased to about 6.0 to 6.8, but from 72 to 120 hours the pH rose and became 7.5 to 8.6. The production of kanamycin was apparent after 48 hours and, depending on the media; the maximum production was found after 72 to 120 hours.
The yield was highest with starch or dextrin, intermediate and about the same with sucrose, glucose, maltose and lactose and poorest with glycerol. Kanamycin was produced by media containing soybean meal, peanut meal, cottonseed meal, corn steep liquor, peptone, yeast extract or meat extract, with or without sodium nitrate. Commercially available soybean meal was recognized to be one of the best nitrogen sources. The addition of corn steep liquor, peptone, yeast extract or nitrate to the soybean meal promoted the production of kanamycin.
The brownish white kanamycin (5 g) was dissolved in 50 ml of 60% aqueous methanol, insoluble material was removed and to the filtrate 40 ml of 60% aqueous methanol containing 2,000 mg of ammonium sulfate was added, and the precipitated kanamycin sulfate was collected, washed with 50 ml of 80% aqueous methanol, and dried. Thus, 4.5 g of kanamycin sulfate was obtained as a light brownish powder.

Therapeutic Function

Antibacterial

Clinical Use

Kanamycin Sulfate was isolated in 1957 by Umezawaand coworkers from Streptomyces kanamyceticus. Its activityagainst mycobacteria and many intestinal bacteria, aswell as several pathogens that show resistance to other antibiotics,brought a great deal of attention to this antibiotic.As a result, kanamycin was tested and released for medicaluse in a very short time.
The use of kanamycin in the United States usually is restrictedto infections of the intestinal tract (e.g., bacillarydysentery) and to systemic infections arising from Gramnegativebacilli (e.g., Klebsiella, Proteus, Enterobacter, andSerratia spp.) that have developed resistance to other antibiotics.It has also been recommended for preoperative antisepsisof the bowel. It is absorbed poorly from the intestinaltract; consequently, systemic infections must be treated byintramuscular or (for serious infections) intravenous injections.These injections are rather painful, and the concomitantuse of a local anesthetic is indicated. The use ofkanamycin in the treatment of TB has not been widely advocatedsince the discovery that mycobacteria develop resistancevery rapidly. In fact, both clinical experience andexperimental work indicate that kanamycin developscross-resistance in the tubercle bacilli with dihydrostreptomycin,viomycin, and other antitubercular drugs. Like streptomycin,kanamycin may cause decreased or complete lossof hearing. On development of such symptoms, its useshould be stopped immediately.

KANAMYCIN SULFATESupplier

Wuhan Hongde Yuexin Pharmatech Co.,Ltd Gold
Tel
027-83850116 18164090116
Email
whhdyxchem123@sina.com
Wuhan Hongde Yuexin Pharmatech Co.,Ltd Gold
Tel
027-83855396 15271852016
Email
whhdyxchem@sina.com
Nanjing MeiBo Biological Technology Co., Ltd.
Tel
025-58619198
Email
sales@mbbio.com
XiaoGan ShenYuan ChemPharm co,ltd
Tel
15527768850
Email
1791901229@qq.com
Sichuan Kulinan Technology Co., Ltd
Tel
400-1166-196 18981987031
Email
cdhxsj@163.com